Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Enrollment commences in Exact Sciences' colorectal cancer screening trial

Exact Sciences today announced the initiation of the pivotal trial for the company's multi-marker molecular diagnostic screening test for the early detection of colorectal cancer.

13 Jul 2011

Men more likely to succumb to cancer

According to a new analysis of 36 different types of tumors and blood cancers that affect both sexes, men are more likely than women to get and die of cancer. The report shows that leukemia and cancers of the colon and rectum, pancreas, and liver killed about one and a half to two times as many men as women in the U.S. over a 30-year period. Lung cancer killed nearly two and a half times as many men during that time. According to the American Cancer Society men have about a 1 in 2 chance of developing cancer at some point in their lives, compared with women, who have a 1 in 3 chance.

13 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

Blood tests encourage more people to participate in regular screening for colorectal cancer

Epigenomics AG, the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon's first European CRC Patient Conference, The Power of Patient Voice 2011, showing that patients believe tests using blood samples would encourage more people to participate in regular screening for colorectal cancer.

8 Jul 2011

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.

8 Jul 2011

Study finds large state disparities in progress against colorectal cancer mortality rates

Improvements in colorectal cancer mortality rates are concentrated in the northern part of the United States, while southern states continue to fall behind, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

Progress in reducing colorectal cancer mortality rates varies across U.S. states

Progress in reducing colorectal cancer (CRC) mortality rates varies significantly across states, with rates in the Northeast showing the most progress and those in the South showing the least progress, according to a new study.

7 Jul 2011

High folate intake linked with reduced risk of colorectal cancer

A new study finds high folate intake is associated with a reduced risk of colorectal cancer, a finding consistent with the findings of most previous epidemiologic studies.

6 Jul 2011

Avastin for breast cancer still covered by Medicare despite FDA indecision

The Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug Administration Commissioner Peggy Hamburg decides to withdraw Avastin for such use, according to Don McLeod, a spokesman for the Centers for Medicare and Medicaid. McLeod said, in his statement, “The FDA decision, when it comes, does not affect CMS.”

1 Jul 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Polymedco, Inc. is pleased to announce the direct availability of the BTA stat® test from our sales force – The BTA stat® test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine.

27 Jun 2011

Patients with familial adenomatous polyposis have higher vascular density in mouth

A team led by Johns Hopkins researchers has found that a hereditary colon cancer syndrome, familial adenomatous polyposis (FAP), is associated with abnormally dense blood vessel growth in the skin lining the mouth.

24 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

Panacea Global announces name change

Panacea Global Inc.,, a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.

20 Jun 2011

Cancer Statistics 2011 report finds progress has not benefitted all segments of the population equally

A steady reduction in overall cancer death rates translates to the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society.

18 Jun 2011

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported the issuance of a new U.S. patent, which represents a significant addition to DiagnoCure's PCA3 prostate cancer biomarker portfolio.

16 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Enrollment commences in Exact Sciences' colorectal cancer screening trial

Men more likely to succumb to cancer

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Blood tests encourage more people to participate in regular screening for colorectal cancer

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Study finds large state disparities in progress against colorectal cancer mortality rates

Study finds link between genetic variation and cetuximab rectal cancer therapy

Progress in reducing colorectal cancer mortality rates varies across U.S. states

High folate intake linked with reduced risk of colorectal cancer

Avastin for breast cancer still covered by Medicare despite FDA indecision

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Patients with familial adenomatous polyposis have higher vascular density in mouth

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

Panacea Global announces name change

Cancer Statistics 2011 report finds progress has not benefitted all segments of the population equally

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Galectin strengthens cancer drug patent portfolio in Europe

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in